Form 4: Bicycle Therapeutics Officer Sells Shares to Cover Tax Obligations

Bicycle Therapeutics' Chief Product & Supply Chain Officer, Michael Charles Ferguson Hannay, sold a total of 722 ordinary shares to cover statutory tax withholding obligations related to restricted stock unit vesting.

Summary

• Michael Charles Ferguson Hannay, the Chief Product & Supply Chain Officer of Bicycle Therapeutics PLC (BCYC), reported two sales of ordinary shares.
• On July 2, 2025, 474 ordinary shares were sold at a weighted average price of $7.09 per share, with prices ranging from $7.09 to $7.14.
• On July 3, 2025, an additional 248 ordinary shares were sold at a weighted average price of $7.44 per share, with prices ranging from $7.405 to $7.44.
• These sales were non-discretionary 'sell to cover' transactions, mandated by the reporting person's award agreement to satisfy minimum statutory tax withholding obligations upon the vesting and settlement of restricted stock units.
• Following these transactions, Michael Charles Ferguson Hannay beneficially owns 53,825 ordinary shares directly.

Sentiment

Score: 5

Explanation: The transaction is a non-discretionary 'sell to cover' for tax purposes, which is a neutral event and does not indicate management's view on the company's future prospects.

Positives

• The share sales were non-discretionary, specifically mandated to cover statutory tax withholding obligations, rather than a voluntary sale indicating a lack of confidence.
• The Chief Product & Supply Chain Officer retains a significant beneficial ownership of 53,825 ordinary shares after the transactions.

Negatives

• The officer's direct beneficial ownership of ordinary shares decreased by a total of 722 shares due to the sales.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it is solely a report of an insider transaction.

Management Comments

• The sale represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units.
• This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary sale by the Reporting Person.

Industry Context

This Form 4 filing reports a routine insider transaction for tax purposes, which is a common occurrence for executives receiving equity compensation. It does not reflect broader industry trends or specific competitive dynamics within the biotechnology or pharmaceutical sectors.

Comparison to Industry Standards

• The 'sell to cover' mechanism for satisfying tax obligations on equity vesting is a standard practice across industries, including biotechnology, and is widely used by executives in publicly traded companies.
• This type of transaction is generally viewed as a neutral event, distinct from discretionary sales that might signal an insider's view on the company's future prospects, aligning with common industry interpretations of such filings.

Stakeholder Impact

• Shareholders may note the reduction in the officer's direct holdings, but the non-discretionary nature of the sale for tax purposes mitigates concerns about insider sentiment.

Key Dates

Recommendation

Keywords

Bicycle Therapeutics, BCYC, Form 4, insider transaction, share sale, tax withholding, restricted stock units, RSU, Michael Hannay, officer